AsepticFill.com

Aseptic filling versus terminal sterilization

An aseptic fill puts a sterile product into sterile containers under conditions that keep it sterile, because nothing sterilizes the sealed unit afterwards. The FDA's 2004 guidance draws the line: in terminal sterilization the container is filled, sealed and then sterilized by heat or radiation; in an aseptic process the drug, container and closure are sterilized separately and brought together, so "it is critical that containers be filled and sealed in an extremely high-quality environment".2 Regulators prefer the first route. The EMA's sterilization guideline calls terminal sterilization "the method of choice whenever possible",3 and Annex 1 says it "provides a greater assurance of sterility".1 But "the majority of ATMPs cannot be terminally sterilised",4 and the FDA notes that cellular therapy products may be aseptically processed in their entirety.2

The fill-finish sequence, step by step

Fill-finish is the shorthand for everything between bulk drug substance and a sealed, inspected unit. Annex 1 puts the core of it in grade A: aseptic assembly of the filling equipment, compounding, "aseptic filling, sealing of containers such as ampoules, vial closure, transfer of open or partially stoppered vials" and lyophilizer loading.1

• Bioburden and sterile filtration. The bulk is tested immediately before filtration (the EMA accepts not more than 10 CFU per 100 ml in most situations)3 and passed through a sterilizing-grade filter of at most 0.22 µm, integrity-tested before use (PUPSIT) and after.1
• Filling and closing. Vials, syringes, cartridges or bags are filled and closed under first air, the filtered air that reaches the product before touching anything else.1
• Freeze-drying, where used. Partially stoppered vials travel to the lyophilizer under grade A at all times; Annex 1 treats the step as an extension of aseptic processing.1
• Capping and inspection. Capping runs with grade A air supply, and every filled container of a parenteral product is inspected individually for contamination or defects.1

Single-use bags, filters, tubing and connectors now carry much of this; Annex 1 lists extractables, leachables, fragility and the extra manual connections as risks for the contamination control strategy to weigh.1

Cleanroom grades, isolators and RABS

Under Annex 1, grade A is the critical zone for the filling line, stopper bowl and open containers; grade B is its background where no isolator is used; grades C and D serve less critical steps.1 Grade A allows 3,520 particles of 0.5 µm or larger per cubic metre, at rest and in operation, the same limit as ISO Class 5 under ISO 14644-1,15 which the FDA notes "approximately equals EU Grade A" and the older Class 100.2 For viable contamination the grade A action limit is no growth.1

Annex 1 defines the two barrier technologies. An isolator is a bio-decontaminated enclosure giving "uncompromised, continuous isolation of its interior from the external environment"; a RABS (restricted access barrier system) is enclosed but not fully sealed, with rigid walls and integrated gloves.1 A closed isolator may sit in a grade D background and an open one in grade C, if risk assessment justifies it.1 The FDA guidance devotes an appendix to isolators,2 USP <1116> covers cleanrooms, RABS and isolators alike,6 and the ISPE Baseline Guide covers their integration into facility design.7

Media fills and the contamination control strategy

The 2022 Annex 1 asks every sterile site to run a contamination control strategy, "a planned set of controls for microorganisms, endotoxin/pyrogen and particles", reviewed periodically by management,1 with ICH Q9(R1) risk management behind it.8

The proof that a line can keep product sterile is the media fill, or aseptic process simulation: the line runs with sterile growth medium instead of product, the units are incubated, and any growth is a failure. Annex 1 requires at least three consecutive satisfactory runs for initial validation, a repeat after any significant change, and a target of zero growth.1 The FDA guidance expects semi-annual requalification of each line, annual participation by everyone who enters the aseptic room, and no contaminated units when fewer than 5,000 are filled.2 PDA Technical Report No. 22, revised in 2025, is the industry's detailed guide to designing them.9 For routine monitoring, USP <1116> suggests contamination recovery rates below 0.1% in isolators and closed RABS.6

The rulebook: Annex 1, FDA, WHO and PIC/S

• EU and PIC/S. The revised Annex 1, "Manufacture of Sterile Medicinal Products", was published on 25 August 2022 and came into operation on 25 August 2023, with point 8.123 a year later;1 PIC/S adopted the same text the same day.10
• WHO. TRS 1044 Annex 2, published on 31 October 2022, was prepared with the European Union and PIC/S.11
• United States. 21 CFR 211.113(b) requires "validation of all aseptic and sterilization processes",12 and the FDA's 2004 guidance, which replaced the 1987 guideline, sets out the agency's expectations.2
• Advanced therapies. The EU's GMP guideline for ATMPs applies the same principles, including process simulation and 0.22 µm filtration, to cell and gene therapies.4
• Compounding. USP <797>, official since 1 November 2023, governs sterile compounding in pharmacies rather than GMP manufacturing.13

Where the demand is coming from

The products that need an aseptic fill are getting harder to fill, by the account of the people making them. A 2026 review describes growing demand for high-concentration protein formulations for subcutaneous injection and calls fill-finish "a major limitation", citing aggregation, particulates and viscosity.14 A 2024 review sets out the fill/finish considerations for AAV gene therapies, whose protein-DNA complexes are sensitive to the stresses of manufacturing, shipping and clinical use.15 Each of them ends its manufacturing journey on a sterile filling line, the step this domain names.

Who builds around the name

• Contract manufacturers filling biologics, vaccines and advanced therapies that cannot be terminally sterilized.4
• Makers of filling machines, isolators, RABS and robotic cells, the technologies Annex 1 names to protect the product.1
• Suppliers of sterilizing-grade filters, single-use assemblies, vials, stoppers and ready-to-use components.1
• Consultancies for contamination control strategies, Annex 1 readiness and media-fill design.19
• Training providers: Annex 1 asks for trained, qualified personnel and the FDA for annual media-fill participation.12
• Software for batch records, environmental monitoring and inspection data.1

Aseptic fill, aseptic filling, fill-finish

Annex 1 writes "aseptic filling" and "aseptically filled".1 The FDA guidance says "aseptic processing".2 Journals say "fill-finish" or "fill/finish".1415 On a call, a procurement or quality team says aseptic fill. AsepticFill.com holds that shortest spoken form and reads correctly under every longer one.

AsepticFill.com is a domain name offered for sale by its owner. It is not affiliated with any regulator, standards body, publisher or company named here; sources are cited as background only.

1. EudraLex Volume 4, Annex 1: Manufacture of Sterile Medicinal Products (2022).European Commission; in operation 25 August 2023
2. Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice.U.S. Food and Drug Administration, guidance for industry, 2004
3. Guideline on the sterilisation of the medicinal product, active substance, excipient and primary container.European Medicines Agency, in effect 1 October 2019
4. Guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal Products.European Commission, EudraLex Volume 4 Part IV, 2017
5. ISO 14644-1:2015 Cleanrooms and associated controlled environments, Part 1: Classification of air cleanliness by particle concentration.International Organization for Standardization
6. General Chapter <1116> Microbiological Control and Monitoring of Aseptic Processing Environments.United States Pharmacopeia, USP-NF (subscription record)
7. Baseline Guide Vol 3: Sterile Product Manufacturing Facilities, Third Edition.International Society for Pharmaceutical Engineering, 2018
8. ICH Q9(R1): Quality Risk Management.International Council for Harmonisation, Step 4, January 2023
9. Technical Report No. 22 (Revised 2025): Process Simulation for Aseptically Filled Products.Parenteral Drug Association
10. Entry into force of revised Annex 1 of the PIC/S GMP Guide (PE 009-17).Pharmaceutical Inspection Co-operation Scheme, 2023
11. WHO good manufacturing practices for sterile pharmaceutical products (TRS 1044, Annex 2).World Health Organization, 31 October 2022
12. 21 CFR 211.113: Control of microbiological contamination.Electronic Code of Federal Regulations
13. General Chapter <797> Pharmaceutical Compounding: Sterile Preparations.United States Pharmacopeia; official 1 November 2023
14. Prajapati R et al. Manufacturing process development strategies for high concentration biologic drug products: from downstream processing to fill-finish.Advanced Drug Delivery Reviews, 2026
15. Som M et al. Drug product formulation and fill/finish manufacturing process considerations for AAV-based genomic medicines.Journal of Pharmaceutical Sciences, 2024